Nasdaq Stockholm AB: Bio Vitos Pharma AB receives observation status

Yesterday, on April 15, 2024, Bio Vitos Pharma AB (the "Company") issued a
press release with information that a member of the Company's board of
directors had resigned, resulting in the board of directors consisting of only
two members. 

The rules of Nasdaq First North Growth Market state that an issuer can be given
observation status if any circumstance exists that results in substantial
uncertainty regarding the issuer or the pricing of its financial instruments. 

With reference to the above, Nasdaq Stockholm AB decides that the shares in Bio
Vitos Pharma AB (BIOVIT, ISIN code SE0009320278, order book ID 135098) shall be
given observation status. 

For further information about this exchange notice please contact Enforcement &
Investigations, telephone [phone]. 


Nasdaq Stockholm AB